Clinical Technician - ICU, General

Newmark negotiates $97.5M sale of medical office campus in Fairfax, Virginia. September 24, 2026 FAIRFAX, VA. - Newmark has negotiated the $97.5 million sale of Willow Oaks Medical Campus, a two-building medical office property located at 8260 and 8280 Willow Oaks Corporate Drive in Fairfax, a city in Northern Virginia. Locally based Inova Health System acquired the property from Stockdale Capital Partners. Ben Appel, Jay Miele, Justin Shepherd, John Nero, Michael Greeley and Ron Ott of Newmark represented the seller in the transaction. Newmark's Jud Ryan and James Cassidy supported the transaction. The buildings each span approximately 188,000 square feet and have undergone multimillion-dollar capital investment initiatives into tenant spaces, common areas and amenities in recent years. Willow Oaks is located immediately adjacent to Inova's flagship 923-bed hospital campus and is anchored by the locally based health system, as well as multiple third-party medical users.

Newmark arranges $97.5 million sale of Willow Oaks Medical Campus in Fairfax, VA. September 23, 2026 9:00AM September 23, 2026 9:00 AM Newmark announces the Company has arranged the $97.5 million sale of the Willow Oaks Medical Campus, a 382,850-square-foot, two-building portfolio of medical office buildings ("MOB") located at 8260 and 8280 Willow Oaks Corporate Drive in Fairfax, Virginia. Inova Health System (Moody's Aa2) acquired the portfolio from Stockdale Capital Partners. Co-Heads of U.S. Medical Office Capital Markets Ben Appel, Jay Miele and Justin Shepherd, Head of Healthcare Debt John Nero, Senior Managing Director Michael Greeley and Associate Directors Ron Ott and represented the seller. D.C-area capital markets Executive Managing Directors Jud Ryan and James Cassidy supported the transaction. "The competitive process demonstrated strong investor demand for Willow Oaks, with multiple third-party bids," said Appel. "Initially we only marketed one of the two twin MOBs, but demand for Willow Oaks resulted in unsolicited bids for both assets. The Properties are located immediately adjacent to Inova's flagship 923-bed hospital campus." The MOB's are anchored by Inova, and home to combination of hospital and 3rd party tenancy, creating a healthy ecosystem of services for the community. Each property spans approximately 188,000 square feet and has benefited from multi-million-dollar capital investment initiatives into tenant spaces, common areas and amenities in recent years. Located in the Merrifield submarket, the properties are adjacent to Inova's headquarters and Inova Fairfax Hospital and benefit from connectivity to the Capital Beltway and Dunn Loring-Merrifield Metro station. The portfolio is also proximate to Tysons, Washington, D.C. and the Mosaic District, a major mixed-use destination offering retail, dining and entertainment. About Newmark Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries ("Newmark"), is a world leading commercial real estate advisor and service provider to large institutional investors and other owners, global corporations and other occupiers, and lenders. Built with purpose and driven by excellence, Newmark's comprehensive platform is uniquely tailored to provide superior outcomes to clients. For the twelve months ended June 30, 2026, Newmark generated revenues of more than $3.6 billion. As of June 30, 2026, Newmark and its business partners together operated from over 195 offices with more than 10,000 professionals across four continents. Learn more at nmrk.com or follow @newmark. Discussion of Forward-Looking Statements about Newmark Statements in this document regarding Newmark that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company's business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

Inova Stem Cell Transplant and Immunotherapy Program offers advanced cellular therapy. Inova Schar Cancer is Northern Virginia's only FACT-accredited health system. There is an exciting new frontier in the fight against cancer: Immunotherapy is transforming cancer treatment by harnessing the power of the body's own immune system to identify and attack cancer cells. Inova Schar Cancer is expanding access to these treatments through advanced cellular therapies. Inova is now accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) for stem cell transplant and immune effector cell therapy. This distinction recognizes Inova's adherence to rigorous international standards for quality, safety and excellence in cellular therapy. At Inova Schar Cancer, innovative therapies such as stem cell transplant, tumor-infiltrating lymphocytes (known as TIL), chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are opening new possibilities for cancers that were once considered difficult to treat. For many patients, these therapies offer the promise of long-term remission and, in some cases, a cure. Launched in late 2024, the Inova Stem Cell Transplant and Immunotherapy Program combines advanced clinical care with an integrated, state-of-the-art cell processing laboratory that supports stem cell transplant, CAR-T therapy and other innovative immunotherapy approaches for patients with blood cancers and complex marrow disorders. The team cared for 33 patients in 2025 and is on track to treat even more in 2026. Before this program's launch, patients across Northern Virginia needed to travel to centers hours away for these leading-edge therapies. Because treatment can require an inpatient stay of four to six weeks or longer, receiving care at a distant center can be very difficult for individuals and their families. "Our vision for this program is that it will meet a significant need for cell therapy resources in our region," said Inova hematologist-oncologist Stephen Medlin, DO. "FACT accreditation is important for any program that wants to perform cellular therapy, because it is only awarded to programs that demonstrate the highest standards for safety, quality and outcomes." Comprehensive stem cell transplant and immunotherapy care. The program offers stem cell transplant, cellular therapy and advanced immunotherapy treatments designed to help the immune system better recognize and attack cancer cells. These treatments can be used for a range of blood cancers and other disorders including multiple myeloma, myelodysplastic syndrome, myelofibrosis and acute leukemia, as well as aplastic anemia and sickle cell disease. CAR-T therapy is a specialized immunotherapy approach in which a patient's T-cells are collected and genetically modified to target cancer cells more precisely. Once infused back into the patient's body, these engineered cells help identify and destroy cancer cells. CAR-T is used for lymphoma as well as multiple myeloma. Integrated care designed around the patient. The Inova Stem Cell Transplant and Immunotherapy Program is designed to streamline care by integrating the hospital, cancer program and cell processing laboratory within one coordinated system. This structure supports continuity across evaluation, treatment and recovery while helping simplify care for patients and referring physicians. "We've designed our team to work well with referring providers, ensuring a smooth transition both to our center and then back to the referring provider, so the continuity of care feels seamless from the patient's perspective," Dr. Medlin said. Patients are supported by a multidisciplinary team that includes transplant physicians, hematologists, nurses, immunotherapy specialists and supportive care professionals working together throughout treatment. Recently, Inova's cellular therapy team won Inova's first DAISY Team Award, a national nursing excellence award honoring teams that go above and beyond to provide excellent, compassionate care. "Our DAISY Team Award is an indicator of how dedicated we are to taking a team approach to delivering patient care, both within Inova and with our referring providers as well," Dr. Medlin said. More about Inova's FACT accredited program. Inova's FACT accreditation reflects the health system's commitment to delivering advanced, evidence-based cellular therapy care for patients across the region. "FACT accreditation distinguishes Inova Schar Cancer as a leader in cellular therapy and recognizes the expertise, collaboration and rigorous standards upheld by our team," said Dr. Medlin. "It reinforces our dedication to delivering safe, high-quality, innovative care for our patients." Support beyond treatment. Patients and caregivers also have access to integrated support services through Inova Peterson Life with Cancer(R), including counseling, wellness programs, education and emotional support throughout treatment and recovery. The program's coordinated model allows many patients to receive advanced treatment while remaining connected to their family and support systems during care.